Górny M K, Lawniczak M, Jenek R, Słowik-Gabryelska A, Kaczmarek E, Zeromski J
Department of Clinical Pathomorphology, Academy of Medicine, Poznań, Poland.
Lung. 1988;166(2):97-105. doi: 10.1007/BF02714033.
The sera of patients with lung cancer, nonmalignant lung disease, and blood donors were subjected to various immunologic assays. Nine assays, based on immunoradiometric (IRMA) and immunoenzymatic (ELISA) principles, included 3 types of fetal cell antibodies, 2 established lung cancer cell antibodies, anti-DNA, anti-IgG autoantibodies, and immune complex assays based on C1q binding and anti-C3 activity. Antitumor cell antibody level was significantly lower in patients with lung cancer compared to blood donors. In the remaining 7 assays, the lung cancer patients tended towards higher median values compared to both control patients and blood donors, but without statistical significance, with the exception of anti-DNA antibodies. Statistical analysis of all 9 assays taken together has shown significant differences between the 3 groups. When only 5 assays were used to assess 3 types of fetal cell antibodies, anti-DNA antibodies, and immune complexes by means of ELISA anti-C3, the margins between groups increased. A range of values for the selected assays was established that may discriminate 70% of tested individuals of the 3 groups. These results suggest the existence of a characteristic profile of deranged humoral immunity in lung cancer patients.
对肺癌患者、非恶性肺部疾病患者以及献血者的血清进行了各种免疫学检测。基于免疫放射分析（IRMA）和免疫酶分析（ELISA）原理的九种检测，包括三种类型的胎儿细胞抗体、两种已确定的肺癌细胞抗体、抗DNA、抗IgG自身抗体以及基于C1q结合和抗C3活性的免疫复合物检测。与献血者相比，肺癌患者的抗肿瘤细胞抗体水平显著降低。在其余七种检测中，与对照患者和献血者相比，肺癌患者的中位数往往更高，但除抗DNA抗体外无统计学意义。对所有九种检测进行综合统计分析表明，三组之间存在显著差异。当仅使用五种检测通过ELISA抗C3来评估三种类型的胎儿细胞抗体、抗DNA抗体和免疫复合物时，组间差异增大。确定了所选检测的一系列值，这些值可以区分三组中70%的受试个体。这些结果表明肺癌患者存在体液免疫紊乱的特征性概况。
